Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, Aspinall R, Doerffel Y, Kremer A, Sheridan D, Bacon B, Berg C, Borg B, Hassanein T, Odin J, Shiffman M, Thuluvath PJ, Thorburn D, Bernstein D, Buggisch P, Corless L, Levy C, Mayo MJ, Swain MG, Vierling J, Woerns MA, Steinberg AS, Bergheanu S, Choi YJ, Varga M, Martin R, Mcwherter C, Jones D (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Publisher: ELSEVIER SCIENCE BV

City/Town: AMSTERDAM

Pages Range: S105-S106

Conference Proceedings Title: JOURNAL OF HEPATOLOGY

Event location: Paris

DOI: 10.1016/s0168-8278(18)30429-x

Authors with CRIS profile

Involved external institutions

CymaBay Therapeutic United States (USA) (US) University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US) Asklepios Kliniken Verwaltungsgesellschaft mbH Germany (DE) Donald and Barbara Zucker School of Medicine at Hofstra/Northwell United States (USA) (US) Icahn School of Medicine at Mount Sinai United States (USA) (US) Saberg Clinical Research Netherlands (NL) University of Newcastle (UoN) Australia (AU) Hull and East Yorkshire Hospitals NHS Trust United Kingdom (GB) University of Miami United States (USA) (US) Houston Texas Medical Center United States (USA) (US) Charité - Universitätsmedizin Berlin Germany (DE) Universitätsklinikum Tübingen Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) Germany (DE) Southern Therapy and Advanced Research LLC United States (USA) (US) Queen Alexandra Hospital United Kingdom (GB) Henry Ford Health System (HFHS) United States (USA) (US) Saint Louis University (SLU) United States (USA) (US) University of Calgary Canada (CA) University Hospitals Plymouth NHS Trust United Kingdom (GB) Royal Free Hospital United Kingdom (GB) University of Birmingham United Kingdom (GB) Pinnacle Clinical Research United States (USA) (US) Atlanta Gastroenterology Associates United States (USA) (US) Institute for Digestive Health and Liver Disease United States (USA) (US) University of California Davis (UCDAVIS) United States (USA) (US) Bon Secours Liver Institute of Richmond United States (USA) (US)

How to cite

APA:

Hirschfield, G., Boudes, P., Bowlus, C., Gitlin, N., Michael, G., Harrison, S.,... Jones, D. (2018). Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study. In JOURNAL OF HEPATOLOGY (pp. S105-S106). Paris, FR: AMSTERDAM: ELSEVIER SCIENCE BV.

MLA:

Hirschfield, G., et al. "Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study." Proceedings of the International Liver Congress (ILC), Paris AMSTERDAM: ELSEVIER SCIENCE BV, 2018. S105-S106.

BibTeX: Download